Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer

Molecular and Cellular Biochemistry

Volumn 248, Issue 1-2, 2003, Pages 67-75

  Vishwanatha, Jamboor K ^a   Swinney, Ryan ^a   Banerjee, Abhijit G ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Annexin; Cyclooxygenase; Inflammation; Oral cancer; Smokeless tobacco

Indexed keywords

CYCLOOXYGENASE 2; LIPOCORTIN 1; PEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CARCINOMA CELL; CELL IMMORTALIZATION; CHEEK POUCH; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACT; HAMSTER; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MALE; MEDIATOR; MOUTH CANCER; MOUTH INFLAMMATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMOKELESS TOBACCO; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANIMALS; ANNEXIN A1; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CHEEK; CRICETINAE; CYCLOOXYGENASE 2; DINOPROSTONE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISOENZYMES; MALE; MEMBRANE PROTEINS; MESOCRICETUS; MOUTH NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA; TIME FACTORS; TOBACCO, SMOKELESS; UP-REGULATION;

ANIMALIA; CRICETINAE; NICOTIANA TABACUM;

EID: 0038642503     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024153431272     Document Type: Article

References (76)

1. Kleinman DV, Crossett LS, Ries LAG: Cancers of the Oral Cavity and Pharynx: A Statistics Review Monograph, 1973-1987. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, 1991
2. Gloeckler Ries LA, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK: SEER Cancer Statistics Review 1973-1991. US Department of Health and Human Services, Public Health Service, National Cancer Institute, NIH-94-2789, 1994
3. Silverman S Jr, Gorsky M, Greenspan D: Tobacco usage in patients with head and neck carcinomas: A follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 106: 33-35, 1983
4. Grady D, Greene J, Daniels TE, Ernster VL, Robertson PB, Hauck W, Greenspan D, Greenspan J, Silverman S: Oral mucosal lesions found in smokeless tobacco users. J Am Dent Assoc 121: 117-123, 1990
5. Nam JM, McLaughlin JK, Blot WJ: Cigarette smoking, alcohol, and nasopharyngeal carcinoma: A case-control study among U.S. whites. J Natl Cancer Inst 84: 619-622, 1992
6. Brownson RC, DiLorenzo TM, Van TM, Finger WW: Patterns of cigarette and smokeless tobacco use among children and adolescents. Prev Med 19: 170-180, 1990
7. Tobacco use among high school students - United States. CDC, Atlanta, GA, 1990
8. Giovino GA, Schooley MW, Zhu BP, Chrismon JH, Tomar SL, Peddicord JP, Merritt RK, Husten CG, Eriksen MP: Surveillance for selected tobacco-use behaviors - United States, 1900-1994. MMWR CDC Surveill Summ 43: 1-43, 1994
9. Nelson DE, Tomar SL, Mowery P, Siegel PZ: Trends in smokeless tobacco use among men in four states, 1988-1993. Am J Public Health 86: 1300-1303, 1996.
10. Kessler DA, Barnett PS, Witt A, Zeller MR, Mande JR, Schultz WB: The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco. JAMA 277: 405-409, 1997
11. Report to Congress. Pursuant to the Comprehensive Smokeless Tobacco Health Education Act of 1986. Federal Trade Commission, Washington, D.C., 1995
12. Hoffmann D, Adams JD, Lisk D, Fisenne I, Brunnemann KD: Toxic and carcinogenic agents in dry and moist snuff. J Natl Cancer Inst 79: 1281-1286, 1987
13. Hoffmann D, Rivenson A, Chung F-L, Hecht SS: Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. CRC Crit Rev Toxicol 21: 305-311, 1991
14. Williams HK: Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 53: 165-172, 2000
15. Park N-H, Kang MK: Genetic instability and oral cancer. J Biotechnol 3: 66-71, 2000
16. Anderson JA, Irish JC, McLachlin CM, Ngan BY: H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg 120: 755-760, 1994
17. Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, Gapany S, Gluckman JL: Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 12: 2273-2276, 1992
18. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52: 4832-4836, 1992
19. Shindoh M, Chiba I, Yasuda M, Saito T, Funaoka K Kohgo T, Amemiya A, Sawada Y, Fujinaga K: Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer 76: 1513-1521, 1995
20. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 321-326, 1994
21. Boyle JO, Hakim J, Koch W, van der RP, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480, 1993
22. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res 52: 5997-6000, 1992
23. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schuhmann A, Bosch FX: Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors. Cancer Res 53: 4189-4196, 1993
24. Lee JI, Soria JC, Hassan K, Liu D, Tang X, El Naggar A, Hong WK, Mao L: Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res 61: 837-841, 2001
25. van-der RP, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158, 1994
26. Yamamoto T, Kamata N, Kawano H, Shimizu S, Kuroki T, Toyoshima K, Rikimaru K, Nomura N, Ishizaki R, Pastan I: High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res 46: 414-416, 1986
27. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, Demard F: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13: 132-139, 1991
28. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K: Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 119: 665-668, 1993
29. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R: Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54: 3580-3587, 1994
30. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN: Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: A potential biomarker. J Natl Cancer Inst 85: 971-978, 1993
31. Hansson A, Bloor BK, Haig Y, Morgan PR, Ekstrand J, Grafstrom, RC: Expression of keratins in normal, immortalized and malignant oral epithelia in organotypic culture. Oral Oncol 37: 419-430, 2001
32. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG; Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999
33. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995
34. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998
35. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998
36. Creutz CE: The annexins and exocytosis. Science 258: 924-931, 1992
37. Fava RA, Cohen S: Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. J Biol Chem 259: 2636-2645, 1984
38. Haigler HT, Schlaepfer DD, Burgess WH; Characterization of lipocortin I and an immunologically unrelated 33-kDa protein as epidermal growth factor receptor/kinase substrates and phospholipase A2 inhibitors. J Biol Chem 262: 6921-6930, 1987
39. Pepinsky RB, Sinclair LK: Epidermal growth factor-dependent phosphorylation of lipocortin. Nature 321: 81-84, 1986
40. Meers P, Mealy T, Tauber AI: Annexin I interactions with human neutrophil specific granules: Fusogenicity and coaggregation with plasma membrane vesicles. Biochim Biophys Acta: Bio-Membr 1147: 177-184, 1993
41. Francis JW, Balazovich KJ, Smolen JE, Margolis DI, Boxer LA: Human neutrophil annexin I promotes granule aggregation and modulates Ca(2+)-dependent membrane fusion. J Clin Invest 90: 537-544, 1992
42. Cirino G, Peers SH, Flower RJ, Browning JL, Pepinsky RB: Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci USA 86: 3428-3432, 1989
43. Fradin A, Rothhut B, Poincelot CB, Errasfa M, Russo MF: Inhibition of eicosanoid and PAF formation by dexamethasone in rat inflammatory polymorphonuclear neutrophils may implicate lipocortin 's'. Biochim Biophys Acta 963: 248-257, 1988
44. Wallner BP, Mattaliano, RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browing JL, Ramachandran KL: Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320: 77-81, 1986
45. Blackwell GJ, Carnuccio R, De Rosa M, Flower RJ, Parente L, Persico P: Macrocortin: A polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 287: 147-149, 1980
46. Duncan GS, Peers SH, Carey F, Forder R, Flower RJ: The local anti-inflammatory action of dexamethasone in the rat carrageenin oedema model is reversed by an antiserum to lipocortin 1. Br J Pharmacol 108: 62-65, 1993
47. Perrett IM, Flower RJ: Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J Immunol 150: 992-999, 1993
48. Drost EM, Selby CF, Lannan S, Lowe GD, MacNee W: Changes in neutrophil deformability following in vitro smoke exposure: Mechanism and protection. Am J Respir Cell Mol Biol 6: 287-295, 1992
49. Perretti M, Wheller SK, Choudhury Q, Croxtall JD, Flower RJ: Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N-terminus. Biochem Pharmacol 50: 1037-1042, 1995
50. Vishwanatha JK, Muns G, Beckmann JD, Davis RG, Rubinstein I: Differential expression of annexins I and II in bovine bronchial epithelial cells. Am J Respir Cell and Mol Biol 12: 280-286, 1995
51. Vishwanatha JK, Davis RG, Rubinstein I, Floreani A: Annexin I degradation in bronchoalveolar lavage fluids from healthy smokers: A possible mechanism of inflammation. Clin Cancer Res 4: 2559-2564, 1998
52. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2000
53. Oh JS, Cherrick HM, Park NH: Effect of snuff extract on the replication and synthesis of viral DNA and proteins in cells infected with herpes simplex virus. J Oral Maxillofac Surg 48: 373-379, 1990
54. Hoffmann D, Djordjevic MV: Chemical composition and carcinogenicity of smokeless tobacco. Adv Dent Res 11: 322-329, 1997
55. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P III: Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291: 1196-1203, 1999
56. Gao XP, Vishwanatha JK, Conlon JM, Olopade CO, Rubinstein I: Mechanisms of smokeless tobacco-induced oral mucosa inflammation: Role of bradykinin. J Immunol 157: 4624-4633, 1996
57. Muns G, Vishwanatha JK, Rubinstein I: Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: Role of angiotensin I-converting enzyme. Carcinogenesis 15: 1325-1327, 1994
58. Mangipudy RS, Vishwanatha JK: Role of nitric oxide in the induction of apoptosis by smokeless tobacco extract. Mol Cell Biochem 200: 51-57, 1999
59. Tsueshita T, Gandhi S, Onyuksel H, Rubinstein I: Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1-38). J Appl Physiol 93: 1377-1383, 2002
60. Daffonchio L, Novellini R, Bertuglia S: Protective effect of ketoprofen lysine salt on interleukin-1beta and bradykinin induced inflammatory changes in hamster cheek pouch microcirculation. Inflamm Res 51: 223-228, 2002
61. Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, Han C, Chen J, Huang M T, Yang CS: Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23: 1307-1313, 2002
62. Mangipudy RS, Vishwanatha JK: Role of nitric oxide in the induction of apoptosis by smokeless tobacco extract. Mol Cell Biochem 200: 51-57, 1999
63. Brune B, Golkel C, von KA: Cytokine and low-level nitric oxide prestimulation block p53 accumulation and apoptosis of RAW 264.7 macrophages. Biochem Biophys Res Commun 229: 396-401, 1996
64. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 93: 4816-4820, 1996
65. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999
66. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994
67. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997
68. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929-2934, 1998
69. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998
70. Benowitz NL, Jacob P, Yu L: Daily use of smokeless tobacco: Systemic effects. Ann Intern Med 111: 112-116, 1989
71. Hoffmann D, Hecht SS: Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions. Cancer Res 45: 935-944, 1985
72. Perretti M, Flower RJ, Goulding NJ: The ability of murine leukocytes to bind lipocortin 1 is lost during acute inflammation. Biochem Biophys Res Commun 192: 345-350, 1993
73. Cirino G, Cicala C, Sorrentino L, Ciliberto G, Arpaia G, Perretti M, Flower RJ: Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. Br J Pharmacol 108: 573-574, 1993
74. Goulding NJ, Guyre PM: Lipocortin 1 binding to human leukocytes correlates with its ability to inhibit IgG interactions with Fcgamma receptors. Biochem Biophys Res Commun 192: 351-358, 1993
75. Goulding NJ, Guyre PM: Glucocorticoids, lipocortins and the immune response. Curr Opin Immunol 5: 108-113, 1993
76. Harris JG, Flower RJ, Perretti M: Alteration of neutrophil trafficking by a lipocortin 1 N-terminus peptide. Eur J Pharmacol 279: 149-157, 1995